Ditchcarbon
  • Contact
  1. Organizations
  2. Shire US, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 15 days ago

Shire US, Inc. Sustainability Profile

Company website

Shire US, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1986, the company has achieved significant milestones, including its focus on developing innovative therapies for rare diseases and specialty conditions. Shire is renowned for its core products, particularly in the fields of ophthalmology and rare genetic disorders, with Xiidra being a notable treatment for dry eye disease. The company’s commitment to patient-centric solutions and cutting-edge research distinguishes it in a competitive market. With a strong market position, Shire has garnered recognition for its contributions to improving patient outcomes and advancing healthcare solutions globally.

DitchCarbon Score

How does Shire US, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

72

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Shire US, Inc.'s score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.

82%

Let us know if this data was useful to you

Shire US, Inc.'s reported carbon emissions

Inherited from Shire plc

Shire US, Inc. currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family relationship with Takeda Pharmaceutical Company Limited, from which it inherits climate commitments and initiatives. Shire US, Inc. follows the sustainability and climate strategies set by Takeda, which include various reduction initiatives and targets. These initiatives are cascaded down from Takeda, reflecting a commitment to addressing climate change at multiple levels within the organisation. While specific reduction targets for Shire US, Inc. are not detailed, the overarching goals from Takeda include adherence to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These commitments indicate a proactive approach to managing and reducing carbon emissions across their operations. In summary, while Shire US, Inc. does not provide specific emissions data, it aligns with the climate commitments and reduction strategies established by its parent company, Takeda Pharmaceutical Company Limited, demonstrating a commitment to sustainability and climate action within the pharmaceutical industry.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2016
Scope 1
26,234,000
Scope 2
118,000,000
Scope 3
34,078,000

How Carbon Intensive is Shire US, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Shire US, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Shire US, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Shire US, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Shire US, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Shire US, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Shire US, Inc.'s Emissions with Industry Peers

CSL Behring LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Aptalis Holdings Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 27 days ago

Novo Nordisk Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 15 days ago

Bioverativ Therapeutics Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 hours ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy